Patients with metabolic dysfunction-associated steatotic liver disease have preserved in vitro responses to antiplatelet drugs.

ABSTRACT:

Background

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at a risk of developing cardiovascular disease. Antiplatelet therapy not only prevents cardiovascular disease in these patients, but may also lower the risk of progression into advanced stages of fibrosis. However, patients with MASLD-associated cirrhosis often have complex changes in the hemostatic system and have been excluded from randomized trials.

Objectives

The aim of this study was to assess the potency of antiplatelet drugs in these patients with MASLD-associated cirrhosis.

Methods

We included patients with MASLD-associated cirrhosis (n = 19), patients with type 2 diabetes (DM2) and steatosis (n = 22), patients with steatosis only (n = 15), and he

SUBMITTER: van den Boom BP 

PROVIDER: S-EPMC10704517 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature